$85.1
$60.2 B
CELG Mkt cap, 20-Jul-2018$3.5 B
Celgene Corporation Revenue Q1, 2018Celgene Corporation Gross profit (Q1, 2018)3.4 B
Celgene Corporation Gross profit margin (Q1, 2018), %96.2%
Celgene Corporation Net income (Q1, 2018)846 M
Celgene Corporation EBIT (Q1, 2018)218 M
Celgene Corporation Cash, 31-Mar-20182.8 B
Celgene Corporation Revenue
Celgene Corporation revenue was $13 b in FY, 2017
Celgene Corporation Income Statement
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
Revenue | 6.5 b | 7.7 b | 9.3 b | 11.2 b | 13 b |
Revenue growth, % | 18% | 21% | 21% | ||
Cost of goods sold | 340.4 m | 385.9 m | 420.1 m | 438 m | 461 m |
Gross profit | 6.2 b | 7.3 b | 8.8 b | 10.8 b | 12.5 b |
Gross profit Margin, % | 95% | 95% | 95% | 96% | 96% |
R&D expense | 5.9 b | ||||
General and administrative expense | 2.9 b | ||||
Operating expense total | 8.3 b | ||||
EBIT | 1.8 b | 2.5 b | 2.3 b | 3.2 b | 4.7 b |
EBIT margin, % | 28% | 33% | 24% | 28% | 36% |
Interest expense | 91.6 m | 176.1 m | 310.6 m | 500.1 m | |
Pre tax profit | 1.7 b | 2.3 b | 2 b | 2.4 b | 4.3 b |
Income tax expense | 215.5 m | 327.5 m | 421.5 m | 373.3 m | 1.4 b |
Net Income | 1.4 b | 2 b | 1.6 b | 2 b | 2.9 b |
- Source: SEC Filings
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.3 b | 2.3 b | 2.5 b | 2.8 b | 3 b | 3 b | 3.3 b | 3.3 b | 3.5 b | |||||
Cost of goods sold | 100.8 m | 109.9 m | 105.9 m | 110.9 m | 107.7 m | 113 m | 111 m | 118 m | 135 m | |||||
Gross profit | 2.2 b | 2.2 b | 2.4 b | 2.6 b | 2.9 b | 2.8 b | 3.2 b | 3.2 b | 3.4 b | |||||
Gross profit Margin, % | 96% | 95% | 96% | 96% | 96% | 96% | 97% | 96% | 96% | |||||
R&D expense | 1.1 b | 1.3 b | 733.2 m | 948.7 m | 1.7 b | 995 m | 835 m | 1.3 b | 2.2 b | |||||
General and administrative expense | 616.8 m | 550.3 m | 543 m | 732.1 m | 698 m | 620 m | 939 m | 608 m | 864 m | |||||
Operating expense total | 1.9 b | 2.3 b | 1.5 b | 1.9 b | 2.6 b | 1.8 b | 2 b | 2.2 b | 3.3 b | |||||
EBIT | 415.8 m | 79.6 m | 1 b | 823.7 m | 411.5 m | 1.1 b | 1.3 b | 1.1 b | 218 m | |||||
EBIT margin, % | 18% | 3% | 40% | 30% | 14% | 38% | 40% | 33% | 6% | |||||
Interest expense | 48.3 m | 88.5 m | 121.9 m | 123.3 m | 127.8 m | 127 m | 126 m | 127 m | 166 m | |||||
Pre tax profit | 470.8 m | (19.9 m) | 921.6 m | 695.1 m | 256.8 m | 1 b | 1.1 b | 991 m | 1 b | |||||
Income tax expense | 114.6 m | 14.2 m | 120.9 m | 96.9 m | 85.4 m | 84 m | 69 m | 3 m | 184 m | |||||
Net Income | 372.5 m | 279.7 m | 597.8 m | 508.5 m | 718.9 m | 356.2 m | (34.1 m) | 800.7 m | 598.2 m | 171.4 m | 941 m | 1.1 b | 988 m | 846 m |
- Source: SEC Filings
Celgene Corporation Balance Sheet
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
Cash | 3.2 b | 4.1 b | 4.9 b | 6.2 b | 7 b |
Inventories | 340.4 m | 393.1 m | 443.4 m | 497.9 m | 541 m |
Current Assets | 7.6 b | 9.7 b | 9.4 b | 10.9 b | 14.9 b |
PP&E | 593.4 m | 642.6 m | 814.1 m | 929.8 m | 1.1 b |
Goodwill | 2 b | 2.2 b | 4.9 b | 4.9 b | 4.9 b |
Total Assets | 13.4 b | 17.3 b | 27.1 b | 28.1 b | 30.1 b |
Accounts Payable | 156.2 m | 198.2 m | 240.8 m | 247.1 m | 305 m |
Short-term debt | 544.8 m | 605.9 m | 500.7 m | ||
Current Liabilities | 1.9 b | 2.1 b | 2 b | 3 b | 3 b |
Long-term debt | |||||
Total Debt | 544.8 m | 605.9 m | 500.7 m | ||
Total Liabilities | 23.2 b | ||||
Additional Paid-in Capital | 8.7 b | 9.8 b | 11.1 b | 12.4 b | 13.8 b |
Retained Earnings | 4.5 b | 6.5 b | 8.1 b | 10.1 b | 13.1 b |
Total Equity | 5.6 b | 6.5 b | 5.9 b | 6.6 b | 6.9 b |
Debt to Equity Ratio | 0.1 x | 0.1 x | 0.1 x | ||
Debt to Assets Ratio | 0 x | 0 x | 0 x | ||
Financial Leverage | 2.4 x | 2.7 x | 4.6 x | 4.3 x | 4.4 x |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 2.4 b | 2.4 b | 3.2 b | 3.7 b | 4.4 b | 4.5 b | 6 b | 4.4 b | 5.1 b | 5.5 b | 5.3 b | 6.7 b | 5.5 b | 2.8 b |
Inventories | 313.3 m | 347.8 m | 360 m | 372 m | 386.7 m | 414.3 m | 420.9 m | 470.6 m | 490.4 m | 507.9 m | 509 m | 533 m | 537 m | 536 m |
Current Assets | 7.6 b | 6.9 b | 8.1 b | 8.8 b | 9.7 b | 9.9 b | 10.2 b | 8.4 b | 9.2 b | 9.6 b | 11.6 b | 13.1 b | 14.8 b | 7.9 b |
PP&E | 592.3 m | 595.7 m | 605.1 m | 623.6 m | 649.7 m | 675.2 m | 702 m | 840 m | 854 m | 891.3 m | 958 m | 989 m | 1 b | 1.3 b |
Goodwill | 2 b | 2 b | 2.2 b | 2.2 b | 2.2 b | 2.2 b | 4.7 b | 4.9 b | 4.9 b | 4.9 b | 4.9 b | 4.9 b | 4.9 b | 8 b |
Total Assets | 13.6 b | 12.7 b | 15.6 b | 16.4 b | 17.5 b | 17.7 b | 27.4 b | 26 b | 26.6 b | 26.8 b | 28.8 b | 30.3 b | 31.7 b | 34.6 b |
Accounts Payable | 139.6 m | 149.4 m | 184.5 m | 196.7 m | 204 m | 204.9 m | 189.4 m | 219.7 m | 229.8 m | 235.4 m | 240 m | 272 m | 263 m | 320 m |
Short-term debt | 405.9 m | 869.8 m | 192.3 m | 100 m | 504.4 m | 1.4 b | 1.2 b | 501 m | 500 m | 500 m | 1.4 b | |||
Current Liabilities | 1.9 b | 2.4 b | 1.5 b | 1.4 b | 2.1 b | 3 b | 3.1 b | 1.8 b | 2 b | 2.6 b | 2.6 b | 3.2 b | 4 b | 3.1 b |
Total Debt | 405.9 m | 869.8 m | 192.3 m | 100 m | 504.4 m | 1.4 b | 1.2 b | 501 m | 500 m | 500 m | 1.4 b | |||
Total Liabilities | 7.7 b | 8.2 b | 10.8 b | 10.6 b | 10.7 b | 11.4 b | 22 b | 20.9 b | 21 b | 21.1 b | 21.2 b | 21.9 b | 21.9 b | 29.4 b |
Additional Paid-in Capital | 8.5 b | 8.9 b | 9.2 b | 9.4 b | 10.2 b | 10.5 b | 10.8 b | 11.4 b | 11.7 b | 12 b | 12.7 b | 13.2 b | 13.6 b | 14.1 b |
Retained Earnings | 4.3 b | 4.8 b | 5.4 b | 5.9 b | 7.2 b | 7.5 b | 7.5 b | 8.9 b | 9.5 b | 9.6 b | 11 b | 12.1 b | 13.1 b | 14.4 b |
Total Equity | 6.3 b | 5.4 b | 5.1 b | 5.5 b | 5.7 b | 7.6 b | 8.4 b | 9.9 b | 5.2 b | |||||
Financial Leverage | 2.8 x | 5.1 x | 5.1 x | 4.8 x | 4.7 x | 3.8 x | 3.6 x | 3.2 x | 6.7 x |
Celgene Corporation Cash Flow
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
Net Income | 1.4 b | 2 b | 1.6 b | 2 b | 2.9 b |
Depreciation and Amortization | 134 m | ||||
Accounts Receivable | (101.4 m) | (166.3 m) | (304.7 m) | (222.4 m) | (236 m) |
Inventories | (89.7 m) | (56.5 m) | (50.6 m) | (55.3 m) | (42 m) |
Cash From Operating Activities | 2.2 b | 2.8 b | 2.5 b | 4 b | 5.2 b |
Cash From Investing Activities | (528.6 m) | (1.4 b) | (6.3 b) | (1 b) | (2.9 b) |
Long-term Borrowings | (513.9 m) | (1.9 b) | |||
Cash From Financing Activities | (553.7 m) | (417.4 m) | 4.6 b | (1.6 b) | (1.6 b) |
Interest Paid | 90.8 m | 196.2 m | 243.3 m | 527.2 m | 539 m |
Income Taxes Paid | 291.9 m | 294.6 m | 361.1 m | 373 m | 475 m |
Free Cash Flow | 2.3 b | 3 b | 2.8 b | 4.2 b | 5 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.2 b | 279.7 m | 877.5 m | 1.4 b | 718.9 m | 1.1 b | 1 b | 800.7 m | 1.4 b | 1.6 b | 941 m | 2 b | 3 b | 846 m |
Depreciation and Amortization | 71.8 m | 25.5 m | 52.1 m | 78.1 m | 28.1 m | 57.8 m | 86.6 m | 29.2 m | 58.5 m | 89.6 m | 32 m | 66 m | 100 m | 126 m |
Accounts Receivable | (138.7 m) | (9.8 m) | (61.8 m) | (46 m) | (59.5 m) | (140.9 m) | (145.8 m) | 23.1 m | (80.7 m) | (143.8 m) | 17 m | (75 m) | (139 m) | (47 m) |
Inventories | (62.6 m) | (7 m) | (19.1 m) | (33.6 m) | 7.3 m | (19.2 m) | (27.1 m) | (25.6 m) | (45.2 m) | (62.3 m) | (10 m) | (32 m) | (37 m) | 6 m |
Cash From Operating Activities | 1.7 b | 557.1 m | 1.1 b | 2 b | 856.5 m | 1.1 b | 1.4 b | 974.9 m | 1.9 b | 2.6 b | 853 m | 2.5 b | 3.6 b | (325 m) |
Cash From Investing Activities | (1.4 b) | (220.1 m) | (1.2 b) | (1.4 b) | 338 m | 239.7 m | (5.9 b) | (110.2 m) | (185.6 m) | (298 m) | (1.7 b) | (1.6 b) | (4 b) | (5.7 b) |
Cash From Financing Activities | 103.7 m | (1.2 b) | 110 m | (65.9 m) | (908.1 m) | (951.3 m) | 6.4 b | (1.3 b) | (1.5 b) | (1.7 b) | 1.8 b | |||
Interest Paid | 67.4 m | 52.2 m | 75.9 m | 126.2 m | 50.2 m | 120.2 m | 171.1 m | 200.9 m | 264.8 m | 463.3 m | 198 m | 262 m | 461 m | 190 m |
Income Taxes Paid | 226.2 m | 96.6 m | 193.4 m | 275 m | 106.7 m | 247.2 m | 345.6 m | 102.1 m | 227.1 m | 345.1 m | 128 m | 333 m | 450 m | 387 m |
Free Cash Flow | 1.6 b | 532.4 m | 1 b | 1.9 b | 814.2 m | 1 b | 1.3 b | 915.3 m | 1.8 b | 2.5 b | 791 m | 2.3 b | 3.4 b | (413 m) |
Celgene Corporation Ratios
| USD | Y, 2018 |
|---|---|
Financial Leverage | 6.7 x |
Report incorrect company information
Celgene Corporation Operating Metrics
| FY, 2016 | |
|---|---|
Active Clinical Studies | 52 |
Report incorrect company information
